Get the Stockscreener App
84.43
3.66%
-3.2507
Rhythm Pharmaceuticals Inc stock is traded at $84.43, with a volume of 172.05K.
It is down -3.66% in the last 24 hours and down -16.61% over the past month.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
See More
Previous Close:
$87.68
Open:
$86.21
24h Volume:
172.05K
Relative Volume:
0.22
Market Cap:
$5.77B
Revenue:
$189.76M
Net Income/Loss:
$-196.54M
P/E Ratio:
-27.16
EPS:
-3.1087
Net Cash Flow:
$-156.63M
1W Performance:
-6.17%
1M Performance:
-16.61%
6M Performance:
-14.28%
1Y Performance:
+61.54%
1-Day Range:
$84.02
$87.25
1-Week Range:
$82.00
$92.69
52-Week Range:
$45.91
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals Inc
Sector
Industry
Phone
857-264-4280
Address
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
84.57 | 6.18B | 189.76M | -196.54M | -156.63M | -3.1087 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.65 | 118.41B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.46 | 80.02B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.73 | 43.52B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.96 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
281.89 | 32.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Initiated | RBC Capital Mkts | Outperform |
| Nov-25-25 | Initiated | Citigroup | Buy |
| Nov-05-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-10-25 | Initiated | Goldman | Buy |
| Jul-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-07-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Jan-02-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Guggenheim | Buy |
| Sep-18-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | JMP Securities | Mkt Outperform |
| May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-01-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Aug-08-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-05-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-22 | Reiterated | Needham | Buy |
| Mar-02-22 | Resumed | Stifel | Buy |
| Feb-17-22 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-14-21 | Resumed | Goldman | Neutral |
| Aug-04-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-04-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-30-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-08-20 | Initiated | Goldman | Sell |
| Jul-12-19 | Upgrade | Stifel | Hold → Buy |
| Jul-08-19 | Initiated | Canaccord Genuity | Buy |
| Mar-13-19 | Initiated | Ladenburg Thalmann | Buy |
| Sep-07-18 | Resumed | Morgan Stanley | Overweight |
| Jun-25-18 | Reiterated | Needham | Buy |
| Jun-15-18 | Reiterated | Needham | Buy |
| Oct-30-17 | Initiated | BofA/Merrill | Buy |
| Oct-30-17 | Initiated | Needham | Buy |
View All
Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News
Rhythm Pharmaceuticals: EMANATE Setback but Validated MC4R Mechanism and Pipeline Optionality Support Lowered $100 Buy Rating - TipRanks
HC Wainwright & Co. Lowers Price Target for Rhythm Pharmaceutica - GuruFocus
Focus Shifts To Rhythm’s Imcivree Hypothalamic Obesity Opportunity After Phase III Miss - Citeline News & Insights
A Look At Rhythm Pharmaceuticals (RYTM) Valuation After Recent Share Weakness And Strong Long Term Returns - Yahoo Finance
Is It Too Late To Consider Rhythm Pharmaceuticals (RYTM) After Its 4x Three Year Surge? - simplywall.st
Wall Street Recap: Can Rhythm Pharmaceuticals Inc ride the EV waveSwing Trade & Daily Profit Maximizing Tips - baoquankhu1.vn
Rhythm Pharmaceuticals Inc (RYTM) Stock Price, Quote, News & History - Benzinga
RYTM: Morgan Stanley Lowers Price Target to $136 While Maintaini - GuruFocus
Rhythm Pharmaceuticals Misses The Beat In Obesity, But There's A Caveat - Investor's Business Daily
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Lowered to $131.00 at Citigroup - MarketBeat
Post-Emanate, Rhythm’s next Imcivree news aHO lot better? - BioWorld MedTech
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Lowered to $130.00 at Royal Bank Of Canada - MarketBeat
RBC cuts Rhythm Pharmaceuticals stock price target on trial miss By Investing.com - Investing.com Canada
Citizens Lowers Price Target for Rhythm Pharmaceuticals (RYTM) While Maintaining Rating | RYTM Stock News - GuruFocus
Citizens Jmp Cuts Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $152.00 - MarketBeat
Needham cuts Rhythm Pharmaceuticals stock price target on trial miss By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals (RYTM) Analyst Rating Update: Price Targe - GuruFocus
RYTM: Morgan Stanley Lowers Price Target to $136 While Maintaining Overweight Rating | RYTM Stock News - GuruFocus
Needham & Company LLC Lowers Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $130.00 - MarketBeat
Morgan Stanley Issues Pessimistic Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Given New $139.00 Price Target at Bank of America - MarketBeat
Stock Market Today: Dow, S&P 500 Futures Tick Up As Oil Prices Rise, US Allies Reject Trump's Hormuz Call— Uber, Lululemon, Cisco In Focus (UPDATED) - Benzinga
RYTM: Needham Maintains Buy Rating While Lowering Price Target | - GuruFocus
Rhythm Pharmaceuticals Rare Obesity Drug Study Disappoints - Benzinga
RBC Lowers Price Target on Rhythm Pharmaceuticals to $130 From $140, Keeps Outperform, Speculative Risk - marketscreener.com
Rhythm Pharmaceuticals, Inc. $RYTM Shares Bought by Aquatic Capital Management LLC - MarketBeat
Stocks Showing Improving Market Leadership: Rhythm Pharmaceuticals Earns 81 RS Rating - Investor's Business Daily
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Topline Results and Insights from Phase 3 EMANATE TrialSlideshow (NASDAQ:RYTM) 2026-03-17 - Seeking Alpha
Rhythm Pharma shares fall as obesity drug trial fails to meet main goal - Investing.com South Africa
Stifel reiterates Rhythm Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial - Bitget
Rhythm Pharmaceuticals Reports Mixed Phase 3 EMANATE Results - TipRanks
Rhythm Pharmaceuticals (RYTM) Shares Results from EMANATE Trial - GuruFocus
Trust for Rhythm Pharmaceuticals (RYTM) director receives 4,199 shares - Stock Titan
Rhythm Pharma's obesity drug fails to meet main goal in late-stage trial - marketscreener.com
Rhythm Pharmaceuticals: Rare Genetic Obesity Player With Upcoming PDUFA (NASDAQ:RYTM) - Seeking Alpha
Rhythm Pharmaceuticals Q4 Beat Sets Stage For March 20th PDUFA Decision (NASDAQ:RYTM) - Seeking Alpha
First Light Asset Management LLC Takes $18.23 Million Position in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Cinctive Capital Management LP Sells 35,781 Shares of Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Checkpoint Capital L.P. Has $77.13 Million Position in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Algert Global LLC Increases Stake in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Integral Health Asset Management LLC Increases Stock Position in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Early FDA, Japan Filings For Setmelanotide In Hypothalamic Obesity Might Change The Case For Investing In Rhythm Pharmaceuticals (RYTM) - Sahm
Institution Moves: Is Rhythm Pharmaceuticals Inc vulnerable to short sellers2026 Price Targets & Long Hold Capital Preservation Plans - baoquankhu1.vn
Wells Fargo Maintains Overweight, Raises Price Target for RYTM t - GuruFocus
Wells Fargo raises Rhythm Pharmaceuticals price target on revenue By Investing.com - Investing.com Australia
Wells Fargo raises Rhythm Pharmaceuticals price target on revenue - Investing.com
598,247 Shares in Rhythm Pharmaceuticals, Inc. $RYTM Purchased by Capital Research Global Investors - MarketBeat
Rhythm Pharmaceuticals discloses 18.8% BMI drop in rare obesity patients - MSN
FDA Accepts a New Drug Application From Rhythm Pharmaceuticals (RYTM) - MSN
Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):